Takeda to invest up to $10 million in new Russian production facility for Ninlaro

20 August 2018

Japanese drugmaker Takeda Pharmaceutical (TYO: 4502) plans to invest up to $10 million in the establishment of production of an innovative orphan drug for multiple myeloma patients, according to some Russian media reports.

The company said the new drug is Ninlaro (ixazomib), and its production will be officially started at the company’s plant in the Russian Yaroslavl region in December of the current year, reports The Pharma Letter’s local correspondent.

According to Maciej Fabyanchyk, director of Takeda’s Yaroslavl plant, planned production volumes of the drug are 200,000 capsules per year. The company may increase production in the event that exports of Ninlaro are started.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK